📊 ACET Key Takeaways
Is Adicet Bio, Inc. (ACET) a Good Investment?
Adicet Bio is a pre-revenue biotech company with significant operating losses (-$21.6M) and negative free cash flow (-$21.5M), burning approximately $21.5M annually against a $36.2M cash base (~1.7 years of runway). While the company maintains a strong balance sheet with zero debt and 7.65x current ratio, the absence of revenue generation combined with substantial cash burn presents material fundamental weakness without demonstrated path to profitability.
Adicet Bio’s fundamentals reflect a pre-revenue biotech with persistent operating losses, negative returns on assets and equity, and substantial free cash outflow. The balance sheet is currently clean and liquid, but the business lacks revenue support and is dependent on its cash runway to fund ongoing R&D and operations.
Adicet Bio, Inc. Key Strengths (ACET)
- Strong balance sheet with $169.4M total assets and zero debt (Debt/Equity 0.00x)
- Excellent liquidity position with 7.65x current ratio and $36.2M cash on hand
- Stockholders' equity of $140.1M provides capital buffer for operations
- Improving loss trajectory with EPS improving 20.5% YoY (becoming less negative)
- Strong near-term liquidity with a 7.47x current and quick ratio
- Debt-free balance sheet reduces financial leverage risk
- Positive EPS year-over-year improvement indicates some loss compression
ACET Stock Risks: Adicet Bio, Inc. Investment Risks
- No revenue generation - fundamental issue for any operating company
- Significant annual operating losses of $21.6M with negative free cash flow
- Limited cash runway of approximately 1.7 years at current burn rate without additional fundraising
- Typical biotech execution risks: clinical trial failures, FDA approval delays, regulatory setbacks
- Dependency on successful drug development and market approval for viability
- Likely need for dilutive equity financing to extend runway
- No revenue base, leaving the company entirely reliant on external capital or existing cash reserves
- High annual cash burn with negative operating cash flow and free cash flow
- Deeply negative profitability metrics, including operating income, ROE, and ROA
Key Metrics to Watch
- Monthly cash burn rate and runway extension timeline
- Clinical development milestones and FDA approval progress
- Operating cash flow trends and any movement toward cash break-even
- Equity fundraising activities and dilution impact
- R&D spending efficiency and pipeline advancement metrics
- Quarterly operating cash burn relative to cash and equivalents
- Evidence of revenue generation or sustained reduction in operating losses
Adicet Bio, Inc. (ACET) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.65x current ratio provides a solid financial cushion.
ACET Profit Margin, ROE & Profitability Analysis
ACET vs Healthcare Sector: How Adicet Bio, Inc. Compares
How Adicet Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adicet Bio, Inc. Stock Overvalued? ACET Valuation Analysis 2026
Based on fundamental analysis, Adicet Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adicet Bio, Inc. Balance Sheet: ACET Debt, Cash & Liquidity
ACET Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adicet Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-21.33 indicates the company is currently unprofitable.
ACET Revenue Growth, EPS Growth & YoY Performance
Adicet Bio, Inc. Dividends, Buybacks & Capital Allocation
ACET SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adicet Bio, Inc. (CIK: 0001720580)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACET
What is the AI rating for ACET?
Adicet Bio, Inc. (ACET) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACET's key strengths?
Claude: Strong balance sheet with $169.4M total assets and zero debt (Debt/Equity 0.00x). Excellent liquidity position with 7.65x current ratio and $36.2M cash on hand. ChatGPT: Strong near-term liquidity with a 7.47x current and quick ratio. Debt-free balance sheet reduces financial leverage risk.
What are the risks of investing in ACET?
Claude: No revenue generation - fundamental issue for any operating company. Significant annual operating losses of $21.6M with negative free cash flow. ChatGPT: No revenue base, leaving the company entirely reliant on external capital or existing cash reserves. High annual cash burn with negative operating cash flow and free cash flow.
What is ACET's revenue and growth?
Adicet Bio, Inc. reported revenue of N/A.
Does ACET pay dividends?
Adicet Bio, Inc. does not currently pay dividends.
Where can I find ACET SEC filings?
Official SEC filings for Adicet Bio, Inc. (CIK: 0001720580) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACET's EPS?
Adicet Bio, Inc. has a diluted EPS of $-1.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACET's fundamental grade?
Based on our AI fundamental analysis in June 2026, Adicet Bio, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACET stock overvalued or undervalued?
Valuation metrics for ACET: ROE of -14.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACET's AI grade for 2026?
Our dual AI analysis gives Adicet Bio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACET's free cash flow?
Adicet Bio, Inc.'s operating cash flow is $-21.5M, with capital expenditures of $37.0K.
How does ACET compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -14.5% (avg: 15%), current ratio 7.65 (avg: 2).